More Botox, More Filler, More Regret: A 2026 Peer-Reviewed Study Challenges Aesthetic Medicine’s Biggest Assumption

More Botox, More Filler, More Regret: A 2026 Peer-Reviewed Study Challenges Aesthetic Medicine’s Biggest Assumption

📌 Key Takeaways

  • A narrative review published July 16, 2026 in the Journal of Aesthetic Medicine analyzed 45 studies
    and found that higher treatment volume does not proportionally increase patient satisfaction
    —and in many cases, actively reduces it.
  • Botox satisfaction peaked at 40U and dropped to 39% at 80U.
    Conservative filler injection (avg. 1.6 mL) maintained 84% satisfaction at 12 months,
    vs. 75.8% for high-volume injection (avg. 6.65 mL) at 24 months.
  • The three leading predictors of regret: undiagnosed Body Dysmorphic Disorder (BDD),
    uncalibrated patient expectations, and insufficient pre-treatment counseling.
    BDD affects up to 15% of aesthetic medicine patients.
  • For post-GLP-1 patients (Ozempic/Wegovy users), tissue quality improvement
    outperforms volume replacement—and timing matters more than quantity.